Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Analysts' price targets for the vaccine stock show their true feelings about Novavax.

Why Wall Street Thinks Novavax Is a No-Brainer Stock to Buy Right Now

Outshined by rival coronavirus vaccine developers, the stock is hit with a downbeat analyst report from a prominent bank.

Why Novavax Was Tumbling by 12% This Week

Even after the company's first profitable quarter, it's still too early to accumulate NVAX stock as an analyst issues a bearish price target. The post Let the Market's Shakeout Finish Before Buying Novavax Stock appeared first on InvestorPlace.

Let the Market's Shakeout Finish Before Buying Novavax Stock

Moderna

June may be a critical month for both companies.

Better Buy Ahead of FDA Meetings: Moderna vs. Novavax

Why Novavax Stock Is Tumbling Today

American Eagle Outfitters

General Motors

These mind-bogglingly cheap stocks are valued at 3 to 5 times Wall Street's forecast earnings.

3 Deeply Discounted Stocks You'll Wish You Bought on the Dip

Better Buy: Moderna or Novavax?

Novavax, Inc. (NASDAQ: NVAX) shares are trading lower by 14.20% at $50.14. Stocks have been highly volatile following the Federal Reserve's recent 50 basis point rate hike, which has weighed on the Nasdaq heavily.

Why Novavax Shares Are Diving Today

Shares of Novavax Inc. NVAX, -10.11% sank 8.8% in midday trading Friday, after BofA Securities analyst Alec Stranahan recommended investors avoid the COVID-19 vaccine maker, citing a bearish view on continued booster use and increasing competition in the respiratory syncytial virus (RSV) and flu markets. Stranahan initiated coverage of Novavax at underperform and with a $35 stock price target, which implies about 34% downside from current levels.

Novavax stock drops after BofA's bearish call

Pfizer

Different dynamics are at work for these vaccine stocks.

Why Pfizer Stock Is Rising Today While Moderna and Novavax Are Sliding

Although Novavax, Inc's (NASDAQ: NVAX) shares have tanked 59% year to date, there is still room for a further decline, according to BofA Securities. The Novavax Analyst: Alec Stranahan initiated coverage of Novavax with an Underperform rating and a price target of $35.

Novavax Has Limited Pipeline Upside, Says BofA Analyst: What's Next?

Novavax is well off its September 2021 highs. An analyst thinks it could go even lower.

Novavax Gets First Sell Rating Since 2020. It's Got a Covid Vaccine Problem, Analyst Says.

D.R. Horton

Canoo

GrowGeneration Corp

Roblox

Redfin

Teladoc

Although the recent market volatility has presented some cheap prices, you should be leery about certain growth stocks to avoid. The post 7 Growth Stocks to Avoid Until the Market Crashes Again appeared first on InvestorPlace.

7 Growth Stocks to Avoid Until the Market Crashes Again

Aileron Therapeutics

vTv Therapeutics

Looking for oversold biotech stocks? These three have all seen significant drops this year despite promising catalysts for the future.

3 Oversold Biotech Stocks to Buy Now

There might be a path to get there again, but don't hold your breath.

Will Novavax Stock Ever Reach Its All-Time High Again?

Datadog

4 Growth Stocks Billionaire Money Managers Piled Into During the First Quarter

The stock is starting off from a particularly low point.

Could Novavax's Next Step Make It a Multibagger?

Not enough is going right, and there's plenty going awry.

3 Reasons That Novavax Investors Could Be Looking For The Door

The FDA approval is the only hope for Novavax. If you own it, hold NVAX stock until the approval but do not take a new position right now.

Avoid Novavax Stock as Its Hopes Dwindle

Novavax is doing well now, but what about the future?

This Is the Most Important Number From Novavax's Q1 Earnings

If the FDA committee endorses Novavax's shot, the drug regulator is almost certain to rapidly authorize it for use in the U.S.

Novavax confident Covid vaccine will receive FDA authorization in June after delays

A slew of regulatory catalysts could bring delight -- or disaster.

Here's Why June Could Make Or Break These 3 Vaccine Stocks

NVAX missed on Q1 revenue and earnings. The stock is down over 15% post-earnings. NVAX does not have FDA approval in the U.S. for its vaccine. Future orders to COVAX, as part of its GAVI agreement, are unclear.

News for Novavax Stock (NVAX)